Sales from January to June Grow Over 30% Year-on-Year
BioTop Excels Not Only in Enteritis and Diarrhea but Also as a Combination Therapy, Leveraging Strain Differentiation
HanAll Biopharma's pharmaceutical agent 'BioTop' achieved sales of 10.6 billion KRW in the first half of this year, setting a new record for the company's highest-ever performance.
According to HanAll Biopharma on July 8, BioTop recorded annual sales of 17.2 billion KRW last year, representing a 37.1% increase compared to the previous year. In addition, sales for January to June of this year surpassed 10 billion KRW, marking a year-on-year growth of more than 30% for the same period.
The key to BioTop's rapid growth is its proven strains. BioTop is a pharmaceutical product approved for the direct treatment and prevention of diseases. According to the company, the three strains included in the product (Clostridium butyricum, Bacillus subtilis, and Saccharomyces cerevisiae) have demonstrated both therapeutic efficacy and safety through numerous long-term clinical studies.
The main component, Clostridium butyricum, produces 'short-chain fatty acids (butyrate)', which supply energy to colon epithelial cells, strengthen the intestinal barrier, help improve immune function, and are effective in preventing and treating constipation. Bacillus subtilis, known for promoting the secretion of amylase and breaking down carbohydrates, stimulates the growth of beneficial Bifidobacterium species and aids digestion. Saccharomyces cerevisiae has demonstrated outstanding efficacy in treating diarrhea through various clinical studies. Both Clostridium butyricum and Saccharomyces cerevisiae have also been proven effective in treating antibiotic-associated diarrhea.
Recently, as research on the impact of gut health on the entire body has become more active, interest in probiotics that help maintain a balanced gut microbiome has been increasing. The gut is connected to organs such as the brain, liver, and skin through signaling axes, and gut microbiota are transmitted systemically via these axes. Therefore, the balance of gut microbiota is closely linked to the health of each organ, according to key research findings. In particular, short-chain fatty acids produced by Clostridium butyricum have shown potential for treating metabolic diseases such as diabetes and obesity, inflammatory skin diseases, and dry eye syndrome in various studies.
Based on the differentiation of its strains, BioTop has secured a wide range of indications, including ▲improvement of gut health ▲constipation ▲diarrhea ▲abdominal bloating ▲abnormal intestinal fermentation, and is gradually expanding its presence in the prescription market. In addition to its established use for conditions such as enteritis and diarrhea, BioTop is increasingly being prescribed for the prevention and treatment of antibiotic-associated diarrhea and as an adjunct therapy for constipation. As a result, it has ranked first in non-reimbursed outpatient prescriptions for gastrointestinal agents for four consecutive years since 2021.
HanAll Biopharma plans to continue securing successful models for major diseases for which BioTop is prescribed, while also strengthening scientific clinical evidence through investment in clinical research and diversifying its lineup with optimized formulations, ingredients, and dosages for key targets, with the goal of further developing BioTop into a blockbuster product.
Park Sujin, CEO of HanAll Biopharma, stated, "BioTop is one of the most commonly prescribed gastrointestinal agents in clinical practice and is growing into a probiotic brand with clear evidence of efficacy and safety. Through continuous research and development, we aim to grow BioTop into a premium brand with annual sales of 100 billion KRW by 2030."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
